BFC Planning’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.6K Hold
19
– – ﹤0.01% 2405
2026
Q2
$10.2K Hold
19
– – ﹤0.01% 2363
2026
Q1
$9.9K Sell
19
-4
-17% -$1.91K ﹤0.01% 2055
2025
Q4
$13.4K Hold
23
– – ﹤0.01% 1939
2025
Q3
$10.5K Hold
23
– – ﹤0.01% 1893
2025
Q2
$6.96K Hold
23
– – ﹤0.01% 1945
2025
Q1
$7.62K Buy
23
+4
+21% +$1.31K ﹤0.01% 1875
2024
Q4
$5.86K Sell
19
-1
-5% -$281 ﹤0.01% 1963
2024
Q3
$4.24K Buy
+20
New +$5.12K ﹤0.01% 2054

Other funds holding MDGL

BFC Planning's MDGL Position: Q3 2026 in Review

BFC Planning held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2026 at 19 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2405.

BFC Planning first reported a position in MDGL in Q3 2024 and has held it in 9 quarters since. The position peaked at $13.4K in Q4 2025. 340 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • BFC Planning held 19 shares of Madrigal Pharmaceuticals worth $9.6K as of Q3 2026.
  • BFC Planning left its Madrigal Pharmaceuticals share count unchanged in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2405 holding.
  • BFC Planning first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Madrigal Pharmaceuticals position peaked at $13.4K in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.